N/A N=58 Almonds: Digestive Health and Immune Function of Adults and Children
Healthy
Primary: Gut Microbiota Community Composition — -.0116; -0.407; -0.161; -.0498 log (CFU)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=32 mHealth Intervention Supporting HIV Treatment Adherence and Retention
HIV · Adherence · Retention
Primary: Number of Particpatns Who Considered the Intervention Feasible and Acceptable — 20 participants
N/A N=177 Randomized, Open Investigation Evaluating the Efficacy of Nobel Biocare SFB and CFB Implants
Partial Edentulism · Complete Edentulism
Primary: The Primary Endpoint Was the Change in Marginal Bone Levels (in mm) From the Time of Implant Insertion to Follow-up Visits (3,6,12,24,36 and 60 Months). — -0.31; -0.98…
N/A N=164 CLE for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia
Barrett Syndrome · Barrett's Syndrome · Barrett's Esophagus
Primary: Number of Barrett's Esophagus (BE) Participants With a Composite Outcome of "Optimally Treated" — 16; 16 participants
N/A N=85 Improving Basic and Social Cognition in Veterans With Schizophrenia
Schizoaffective Disorder · Schizophrenia
Primary: Mean Test Scores for Facial Emotion Identification. — 45.5; 41.1; 43.8; 45.1 number of correct answers — p=<.001
Phase 2 N=43 Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab
Diabetic Macular Edema
Primary: Overall Mean Change in Visual Acuity Scores at Month 6 Compared to Baseline — 58.8; 67.6; 8.8 letters
Phase 3 N=190 Canadian Active & Maintenance Modified Pentasa Study
Active Ulcerative Colitis · Remission of Ulcerative Colitis
Primary: Active Phase: Proportion of Active Subjects Achieving Overall Improvement — 64.1; 69.2 percentage of participants
Phase 1 N=56 Pharmacodynamics and Efficacy of MK-7288 in Adults With Sleep Apnea (MK-7288-010)
Apnea, Sleep
Primary: Mean Sleep Latency Score on the Maintenance of Wakefulness Test (MWT) for Participants Taking MK-7288 Versus Placebo — 18.66; 18.62; 20.71; 10.50 Minutes
N/A N=66 AMBU AScope2 Fiberoptic Intubation Versus Fastrach Intubating LMA
Supraglottic Airway
Primary: Total Intubation Time — 89.6; 52.1 seconds
N/A N=49 Clinical Evaluation for General Electric (GE) CT System
CT Scanners X Ray
Primary: Image Quality — 4.53; 4.44; 4.63 units on a scale
Phase 4 N=753 Seprafilm® Adhesion Barrier and Cesarean Delivery
Adhesions · Cesarean Section · Delivery, Obstetric
Primary: Incidence of Adhesions — 75.6; 75.9 percentage of patients with adhesions
Phase 2 N=4 Lenalidomide in HTLV-1 Adult T-Cell Leukemia
Adult T Cell Leukemia/Lymphoma
Primary: Response Rate (CR + Cru + PR)
Phase 2 N=49 Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System
Irritation/Irritant
Primary: Skin Irritation (Erythema and Edema) — 0.9; 0.7; 1.1; 1.0 units on a scale
Phase 2 N=29 Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
Liver and Intrahepatic Biliary Tract Cancer · Recurrent Extrahepatic Bile Duct Cancer · Unresectable Extrahepatic Bile Duct Cancer
Primary: Objective Response Rate (CR and PR) — 0; 3 patients
N/A N=38 Immediate Function of NobelSpeedy Shorty and Brånemark System® Mk III Shorty Implants in Daily Use
Partial Edentulism · Complete Edentulism
Primary: Marginal Bone Remodeling — -1.34; -1.38; -1.37; -1.65 mm